SlideShare a Scribd company logo
1 of 28
Download to read offline
December 2011
Pharmacovigilance
Are you concerned enough?
What is Pharmacovigilance (PV)?
The science and activities relating to the detection, assessment,
understanding and prevention of adverse effects or any other
medicine-related problem
– World Health Organization
Pharmaco - Vigilance
 Pharmaco = medicine
 Vigilare = to watch
 alert watchfulness
 wakefulness
 watchfulness in respect of danger; care; caution; circumspection
 the process of paying close and continuous attention
Definition
 Adverse Drug Reaction
 "A response to a drug which is noxious and unintended, and which occurs at
doses normally used in man for the prophylaxis, diagnosis, or therapy of disease,
or for the modification of physiological function."
 Adverse Event
 Any untoward medical occurrence that may present during treatment with a
pharmaceutical product but which does not necessarily have a causal relationship
with this treatment
 Side Effect
 Any unintended effect of a pharmaceutical product occurring at doses normally
used in man which is related to the pharmacological properties of the drug
The Aims of Pharmacovigilance
 To improve patient care and safety
 To improve public health and safety
 To contribute to the assessment of benefit, harm,
effectiveness and risk of medicines
 To promote understanding, education and clinical training
What to Report?
SERIOUS ADRS
 A serious adverse event (experience) or reaction is any
untoward medical occurrence that at any dose:
 results in death,
 is life-threatening,
 requires inpatient hospitalization of prolongation of existing
hospitalization,
 is a congenital anomaly/birth defect.
NOTE: The term “life-threatening” in the definition of “serious” refers to an event
in which the patient was at risk of death at the time of the event; it does not
refer to an event which hypothetically might have caused death if it was more
severe.
Adverse Reactions:Possible Causes
 Intrinsic factors of the drug
 Pharmacological
 Idiosyncratic
 Carcinogenicity, Mutagenicity
 Teratogenicity
 Extrinsic factors
 Adulterants
 Contamination
 Underlying medical conditions
 Interactions
 Wrong usage
What Should be Reported
 New drugs
 Report all suspected reactions including minor ones
 For established or well known drugs
 All serious, unexpected, unusual ADRs
 Change in frequency of a given reaction
 ADRs to generics not seen with innovator products
 ADRs to traditional medicines
What Should be Reported
 All suspected drug-drug, drug-food, drug-food supplement
interactions
 Statement highlighting marine source of supplements such
as glucosamine so that can be avoided by those with allergy
to sea food
 ADRs associated with drug withdrawals
 ADRs due to medication errors
 eg vincristine given IT
 ADRs due to lack of efficacy or suspected pharmaceutical
defects
Why ADRs are important ?
 5% of hospital admissions
 Death of 1 in 1000 medical inpatients
 Complicates drug therapy
 Decrease compliance
Why ADRs are important ?
30 – 50% of all ADRs are preventable
Why do we need
pharmacovigilance?
Why do we need
pharmacovigilance?
Reason 1:
 Humanitarian concern –
 Insufficient evidence of safety from clinical trials
 Animal experiments
 Phase 1 – 3 studies prior to marketing authorization
Why do we need
pharmacovigilance?
Reason 2
 Medicines are supposed to save lives
 Dying from a disease is sometimes unavoidable; dying from a
medicine is unacceptable.
WHO. Geneva 2005
Why do we need
pharmacovigilance?
Reason 3: ADRs are expensive !!
 6.5% of admissions are due to ADRs
 Seven 800-bed hospitals are occupied by ADR patients
Cost of ADRs ?
 ADR related cost to the country exceeds the cost of the
medications themselves
Why do we need
pharmacovigilance?
Reason 4:
 Promoting rational use of medicines and adherence
Pharmacovigilance system
 Records medication related errors
 Analyses those errors
 Implements interventions
 Promotes patient safety
 Prevent 'preventable errors'
Actionable learning system
ARGUS – ARIS Global – Phase Forward (Empirica)
Passive - Proactive
Future Pro-Active State
Risk
Management
Aggregate
Reporting
Signal Detection
Adverse Case
Management
Passive - Proactive
Current Passive State
Risk
Management
Signal Detection
Aggregate
Reporting
What can we do?
What can we do?
 Develop procedures for the identification, reporting and
follow up of adverse drug events
What can we do?
 Assess the current technology used in the drug safety process
and assist in implementation of new systems
What can we do?
 Evaluate data quality and data integrity controls in place
What can we do?
 Prepare risk minimization action plan (RiskMAP)
What can we do?
 Assess current drug safety and pharmacovigilance training
programs
What can we do?
 Reconcile internal processes for recording safety data received
from multiple sources
For more information:
Monica Dema, Manager New
Business Development
973.658.3133
Or
Monica.Dema@RCMT.com
Or
@MonicaDema

More Related Content

Similar to pharmacovigilance-111031093044-phpapp01.pdf

An overview -Pharmacovigilance by Pougang Golmei,m.pharm,RIPANS,Mizoram
An overview -Pharmacovigilance by Pougang Golmei,m.pharm,RIPANS,MizoramAn overview -Pharmacovigilance by Pougang Golmei,m.pharm,RIPANS,Mizoram
An overview -Pharmacovigilance by Pougang Golmei,m.pharm,RIPANS,Mizorampougang golmei
 
Adverse Drug Reaction
Adverse Drug ReactionAdverse Drug Reaction
Adverse Drug ReactionNishu Vora
 
Adverse Drug Reaction
Adverse Drug ReactionAdverse Drug Reaction
Adverse Drug ReactionNishu Vora
 
Adverse Drug Reaction
Adverse Drug ReactionAdverse Drug Reaction
Adverse Drug ReactionNishu Vora
 
Understanding pharmacovigilance
Understanding pharmacovigilanceUnderstanding pharmacovigilance
Understanding pharmacovigilancefinenessinstitute
 
Adverse Drug Reactions.pptx
Adverse Drug Reactions.pptxAdverse Drug Reactions.pptx
Adverse Drug Reactions.pptxAjithJs2
 
Spontaneous Reporting and Prescription Event Monitoring.pptx
Spontaneous Reporting and Prescription Event Monitoring.pptxSpontaneous Reporting and Prescription Event Monitoring.pptx
Spontaneous Reporting and Prescription Event Monitoring.pptxDrRajeshHadia
 
Pharmacovigilance STUDY
Pharmacovigilance STUDYPharmacovigilance STUDY
Pharmacovigilance STUDYSuvarta Maru
 
Pharmacovigilance - an overview
Pharmacovigilance - an overview Pharmacovigilance - an overview
Pharmacovigilance - an overview S S Shiva
 
Pharmacovigilance AN
Pharmacovigilance ANPharmacovigilance AN
Pharmacovigilance ANAhmed Nouri
 
Ashutosh pharmacovigilance
Ashutosh pharmacovigilance Ashutosh pharmacovigilance
Ashutosh pharmacovigilance ASHUTOSH MISHRA
 
Med safety nj ph a 10 10 11 final 3 (97-2003)
Med safety nj ph a 10 10 11 final 3 (97-2003)Med safety nj ph a 10 10 11 final 3 (97-2003)
Med safety nj ph a 10 10 11 final 3 (97-2003)Shaukat Patel MS R.Ph.
 
Med safety nj ph a 10 10 11 final 3 (97-2003)
Med safety nj ph a 10 10 11 final 3 (97-2003)Med safety nj ph a 10 10 11 final 3 (97-2003)
Med safety nj ph a 10 10 11 final 3 (97-2003)Shaukat Patel MS R.Ph.
 

Similar to pharmacovigilance-111031093044-phpapp01.pdf (20)

An overview -Pharmacovigilance by Pougang Golmei,m.pharm,RIPANS,Mizoram
An overview -Pharmacovigilance by Pougang Golmei,m.pharm,RIPANS,MizoramAn overview -Pharmacovigilance by Pougang Golmei,m.pharm,RIPANS,Mizoram
An overview -Pharmacovigilance by Pougang Golmei,m.pharm,RIPANS,Mizoram
 
Adverse Drug Reaction
Adverse Drug ReactionAdverse Drug Reaction
Adverse Drug Reaction
 
Adverse Drug Reaction
Adverse Drug ReactionAdverse Drug Reaction
Adverse Drug Reaction
 
Adverse Drug Reaction
Adverse Drug ReactionAdverse Drug Reaction
Adverse Drug Reaction
 
Understanding pharmacovigilance
Understanding pharmacovigilanceUnderstanding pharmacovigilance
Understanding pharmacovigilance
 
Pharmacovigilance
PharmacovigilancePharmacovigilance
Pharmacovigilance
 
Basics Of Pharmacovigilance
Basics Of PharmacovigilanceBasics Of Pharmacovigilance
Basics Of Pharmacovigilance
 
Adverse Drug Reactions.pptx
Adverse Drug Reactions.pptxAdverse Drug Reactions.pptx
Adverse Drug Reactions.pptx
 
Spontaneous Reporting and Prescription Event Monitoring.pptx
Spontaneous Reporting and Prescription Event Monitoring.pptxSpontaneous Reporting and Prescription Event Monitoring.pptx
Spontaneous Reporting and Prescription Event Monitoring.pptx
 
Pharmacovigilance
PharmacovigilancePharmacovigilance
Pharmacovigilance
 
Pharmacovigilance STUDY
Pharmacovigilance STUDYPharmacovigilance STUDY
Pharmacovigilance STUDY
 
Pharmacovigilance System
Pharmacovigilance SystemPharmacovigilance System
Pharmacovigilance System
 
Pharmacovigilance - an overview
Pharmacovigilance - an overview Pharmacovigilance - an overview
Pharmacovigilance - an overview
 
Pv overview (2)
Pv overview (2)Pv overview (2)
Pv overview (2)
 
Pharmacovigilance AN
Pharmacovigilance ANPharmacovigilance AN
Pharmacovigilance AN
 
Ashutosh pharmacovigilance
Ashutosh pharmacovigilance Ashutosh pharmacovigilance
Ashutosh pharmacovigilance
 
Med safety nj ph a 10 10 11 final 3 (97-2003)
Med safety nj ph a 10 10 11 final 3 (97-2003)Med safety nj ph a 10 10 11 final 3 (97-2003)
Med safety nj ph a 10 10 11 final 3 (97-2003)
 
Med safety nj ph a 10 10 11 final 3 (97-2003)
Med safety nj ph a 10 10 11 final 3 (97-2003)Med safety nj ph a 10 10 11 final 3 (97-2003)
Med safety nj ph a 10 10 11 final 3 (97-2003)
 
Introduction to Pharmacovigilance.pptx
Introduction to Pharmacovigilance.pptxIntroduction to Pharmacovigilance.pptx
Introduction to Pharmacovigilance.pptx
 
Pharmacovigilence
PharmacovigilencePharmacovigilence
Pharmacovigilence
 

More from dabloosaha

Institutional review board or Independent ethics committee.pdf
Institutional review board or Independent ethics committee.pdfInstitutional review board or Independent ethics committee.pdf
Institutional review board or Independent ethics committee.pdfdabloosaha
 
signaldetectionandmanagement-210803014643.pdf
signaldetectionandmanagement-210803014643.pdfsignaldetectionandmanagement-210803014643.pdf
signaldetectionandmanagement-210803014643.pdfdabloosaha
 
lecture05_causality-methods_2018_lareb_who-6-kl.pptx
lecture05_causality-methods_2018_lareb_who-6-kl.pptxlecture05_causality-methods_2018_lareb_who-6-kl.pptx
lecture05_causality-methods_2018_lareb_who-6-kl.pptxdabloosaha
 
guidelines-150703103126-lva1-app6891.pdf
guidelines-150703103126-lva1-app6891.pdfguidelines-150703103126-lva1-app6891.pdf
guidelines-150703103126-lva1-app6891.pdfdabloosaha
 
6-clinicaltrialsflowprocess-140512151315-phpapp02.pdf
6-clinicaltrialsflowprocess-140512151315-phpapp02.pdf6-clinicaltrialsflowprocess-140512151315-phpapp02.pdf
6-clinicaltrialsflowprocess-140512151315-phpapp02.pdfdabloosaha
 
pv-signalandsignaldetection-210915063241.pdf
pv-signalandsignaldetection-210915063241.pdfpv-signalandsignaldetection-210915063241.pdf
pv-signalandsignaldetection-210915063241.pdfdabloosaha
 
aggregatereportingpvkatalysthls-170327013344.pdf
aggregatereportingpvkatalysthls-170327013344.pdfaggregatereportingpvkatalysthls-170327013344.pdf
aggregatereportingpvkatalysthls-170327013344.pdfdabloosaha
 
icsrnarrativewritingkatalysthls-170224043430.pdf
icsrnarrativewritingkatalysthls-170224043430.pdficsrnarrativewritingkatalysthls-170224043430.pdf
icsrnarrativewritingkatalysthls-170224043430.pdfdabloosaha
 
STUDY DESIGNS IN CLINICAL TRIALS.pdf
STUDY DESIGNS IN CLINICAL TRIALS.pdfSTUDY DESIGNS IN CLINICAL TRIALS.pdf
STUDY DESIGNS IN CLINICAL TRIALS.pdfdabloosaha
 

More from dabloosaha (9)

Institutional review board or Independent ethics committee.pdf
Institutional review board or Independent ethics committee.pdfInstitutional review board or Independent ethics committee.pdf
Institutional review board or Independent ethics committee.pdf
 
signaldetectionandmanagement-210803014643.pdf
signaldetectionandmanagement-210803014643.pdfsignaldetectionandmanagement-210803014643.pdf
signaldetectionandmanagement-210803014643.pdf
 
lecture05_causality-methods_2018_lareb_who-6-kl.pptx
lecture05_causality-methods_2018_lareb_who-6-kl.pptxlecture05_causality-methods_2018_lareb_who-6-kl.pptx
lecture05_causality-methods_2018_lareb_who-6-kl.pptx
 
guidelines-150703103126-lva1-app6891.pdf
guidelines-150703103126-lva1-app6891.pdfguidelines-150703103126-lva1-app6891.pdf
guidelines-150703103126-lva1-app6891.pdf
 
6-clinicaltrialsflowprocess-140512151315-phpapp02.pdf
6-clinicaltrialsflowprocess-140512151315-phpapp02.pdf6-clinicaltrialsflowprocess-140512151315-phpapp02.pdf
6-clinicaltrialsflowprocess-140512151315-phpapp02.pdf
 
pv-signalandsignaldetection-210915063241.pdf
pv-signalandsignaldetection-210915063241.pdfpv-signalandsignaldetection-210915063241.pdf
pv-signalandsignaldetection-210915063241.pdf
 
aggregatereportingpvkatalysthls-170327013344.pdf
aggregatereportingpvkatalysthls-170327013344.pdfaggregatereportingpvkatalysthls-170327013344.pdf
aggregatereportingpvkatalysthls-170327013344.pdf
 
icsrnarrativewritingkatalysthls-170224043430.pdf
icsrnarrativewritingkatalysthls-170224043430.pdficsrnarrativewritingkatalysthls-170224043430.pdf
icsrnarrativewritingkatalysthls-170224043430.pdf
 
STUDY DESIGNS IN CLINICAL TRIALS.pdf
STUDY DESIGNS IN CLINICAL TRIALS.pdfSTUDY DESIGNS IN CLINICAL TRIALS.pdf
STUDY DESIGNS IN CLINICAL TRIALS.pdf
 

Recently uploaded

Presiding Officer Training module 2024 lok sabha elections
Presiding Officer Training module 2024 lok sabha electionsPresiding Officer Training module 2024 lok sabha elections
Presiding Officer Training module 2024 lok sabha electionsanshu789521
 
CELL CYCLE Division Science 8 quarter IV.pptx
CELL CYCLE Division Science 8 quarter IV.pptxCELL CYCLE Division Science 8 quarter IV.pptx
CELL CYCLE Division Science 8 quarter IV.pptxJiesonDelaCerna
 
internship ppt on smartinternz platform as salesforce developer
internship ppt on smartinternz platform as salesforce developerinternship ppt on smartinternz platform as salesforce developer
internship ppt on smartinternz platform as salesforce developerunnathinaik
 
भारत-रोम व्यापार.pptx, Indo-Roman Trade,
भारत-रोम व्यापार.pptx, Indo-Roman Trade,भारत-रोम व्यापार.pptx, Indo-Roman Trade,
भारत-रोम व्यापार.pptx, Indo-Roman Trade,Virag Sontakke
 
Employee wellbeing at the workplace.pptx
Employee wellbeing at the workplace.pptxEmployee wellbeing at the workplace.pptx
Employee wellbeing at the workplace.pptxNirmalaLoungPoorunde1
 
“Oh GOSH! Reflecting on Hackteria's Collaborative Practices in a Global Do-It...
“Oh GOSH! Reflecting on Hackteria's Collaborative Practices in a Global Do-It...“Oh GOSH! Reflecting on Hackteria's Collaborative Practices in a Global Do-It...
“Oh GOSH! Reflecting on Hackteria's Collaborative Practices in a Global Do-It...Marc Dusseiller Dusjagr
 
Roles & Responsibilities in Pharmacovigilance
Roles & Responsibilities in PharmacovigilanceRoles & Responsibilities in Pharmacovigilance
Roles & Responsibilities in PharmacovigilanceSamikshaHamane
 
Types of Journalistic Writing Grade 8.pptx
Types of Journalistic Writing Grade 8.pptxTypes of Journalistic Writing Grade 8.pptx
Types of Journalistic Writing Grade 8.pptxEyham Joco
 
Software Engineering Methodologies (overview)
Software Engineering Methodologies (overview)Software Engineering Methodologies (overview)
Software Engineering Methodologies (overview)eniolaolutunde
 
Earth Day Presentation wow hello nice great
Earth Day Presentation wow hello nice greatEarth Day Presentation wow hello nice great
Earth Day Presentation wow hello nice greatYousafMalik24
 
MARGINALIZATION (Different learners in Marginalized Group
MARGINALIZATION (Different learners in Marginalized GroupMARGINALIZATION (Different learners in Marginalized Group
MARGINALIZATION (Different learners in Marginalized GroupJonathanParaisoCruz
 
18-04-UA_REPORT_MEDIALITERAСY_INDEX-DM_23-1-final-eng.pdf
18-04-UA_REPORT_MEDIALITERAСY_INDEX-DM_23-1-final-eng.pdf18-04-UA_REPORT_MEDIALITERAСY_INDEX-DM_23-1-final-eng.pdf
18-04-UA_REPORT_MEDIALITERAСY_INDEX-DM_23-1-final-eng.pdfssuser54595a
 
ECONOMIC CONTEXT - LONG FORM TV DRAMA - PPT
ECONOMIC CONTEXT - LONG FORM TV DRAMA - PPTECONOMIC CONTEXT - LONG FORM TV DRAMA - PPT
ECONOMIC CONTEXT - LONG FORM TV DRAMA - PPTiammrhaywood
 
Meghan Sutherland In Media Res Media Component
Meghan Sutherland In Media Res Media ComponentMeghan Sutherland In Media Res Media Component
Meghan Sutherland In Media Res Media ComponentInMediaRes1
 
call girls in Kamla Market (DELHI) 🔝 >༒9953330565🔝 genuine Escort Service 🔝✔️✔️
call girls in Kamla Market (DELHI) 🔝 >༒9953330565🔝 genuine Escort Service 🔝✔️✔️call girls in Kamla Market (DELHI) 🔝 >༒9953330565🔝 genuine Escort Service 🔝✔️✔️
call girls in Kamla Market (DELHI) 🔝 >༒9953330565🔝 genuine Escort Service 🔝✔️✔️9953056974 Low Rate Call Girls In Saket, Delhi NCR
 
Final demo Grade 9 for demo Plan dessert.pptx
Final demo Grade 9 for demo Plan dessert.pptxFinal demo Grade 9 for demo Plan dessert.pptx
Final demo Grade 9 for demo Plan dessert.pptxAvyJaneVismanos
 
Computed Fields and api Depends in the Odoo 17
Computed Fields and api Depends in the Odoo 17Computed Fields and api Depends in the Odoo 17
Computed Fields and api Depends in the Odoo 17Celine George
 
Framing an Appropriate Research Question 6b9b26d93da94caf993c038d9efcdedb.pdf
Framing an Appropriate Research Question 6b9b26d93da94caf993c038d9efcdedb.pdfFraming an Appropriate Research Question 6b9b26d93da94caf993c038d9efcdedb.pdf
Framing an Appropriate Research Question 6b9b26d93da94caf993c038d9efcdedb.pdfUjwalaBharambe
 

Recently uploaded (20)

Presiding Officer Training module 2024 lok sabha elections
Presiding Officer Training module 2024 lok sabha electionsPresiding Officer Training module 2024 lok sabha elections
Presiding Officer Training module 2024 lok sabha elections
 
CELL CYCLE Division Science 8 quarter IV.pptx
CELL CYCLE Division Science 8 quarter IV.pptxCELL CYCLE Division Science 8 quarter IV.pptx
CELL CYCLE Division Science 8 quarter IV.pptx
 
internship ppt on smartinternz platform as salesforce developer
internship ppt on smartinternz platform as salesforce developerinternship ppt on smartinternz platform as salesforce developer
internship ppt on smartinternz platform as salesforce developer
 
भारत-रोम व्यापार.pptx, Indo-Roman Trade,
भारत-रोम व्यापार.pptx, Indo-Roman Trade,भारत-रोम व्यापार.pptx, Indo-Roman Trade,
भारत-रोम व्यापार.pptx, Indo-Roman Trade,
 
Model Call Girl in Tilak Nagar Delhi reach out to us at 🔝9953056974🔝
Model Call Girl in Tilak Nagar Delhi reach out to us at 🔝9953056974🔝Model Call Girl in Tilak Nagar Delhi reach out to us at 🔝9953056974🔝
Model Call Girl in Tilak Nagar Delhi reach out to us at 🔝9953056974🔝
 
Employee wellbeing at the workplace.pptx
Employee wellbeing at the workplace.pptxEmployee wellbeing at the workplace.pptx
Employee wellbeing at the workplace.pptx
 
“Oh GOSH! Reflecting on Hackteria's Collaborative Practices in a Global Do-It...
“Oh GOSH! Reflecting on Hackteria's Collaborative Practices in a Global Do-It...“Oh GOSH! Reflecting on Hackteria's Collaborative Practices in a Global Do-It...
“Oh GOSH! Reflecting on Hackteria's Collaborative Practices in a Global Do-It...
 
Roles & Responsibilities in Pharmacovigilance
Roles & Responsibilities in PharmacovigilanceRoles & Responsibilities in Pharmacovigilance
Roles & Responsibilities in Pharmacovigilance
 
Types of Journalistic Writing Grade 8.pptx
Types of Journalistic Writing Grade 8.pptxTypes of Journalistic Writing Grade 8.pptx
Types of Journalistic Writing Grade 8.pptx
 
Software Engineering Methodologies (overview)
Software Engineering Methodologies (overview)Software Engineering Methodologies (overview)
Software Engineering Methodologies (overview)
 
TataKelola dan KamSiber Kecerdasan Buatan v022.pdf
TataKelola dan KamSiber Kecerdasan Buatan v022.pdfTataKelola dan KamSiber Kecerdasan Buatan v022.pdf
TataKelola dan KamSiber Kecerdasan Buatan v022.pdf
 
Earth Day Presentation wow hello nice great
Earth Day Presentation wow hello nice greatEarth Day Presentation wow hello nice great
Earth Day Presentation wow hello nice great
 
MARGINALIZATION (Different learners in Marginalized Group
MARGINALIZATION (Different learners in Marginalized GroupMARGINALIZATION (Different learners in Marginalized Group
MARGINALIZATION (Different learners in Marginalized Group
 
18-04-UA_REPORT_MEDIALITERAСY_INDEX-DM_23-1-final-eng.pdf
18-04-UA_REPORT_MEDIALITERAСY_INDEX-DM_23-1-final-eng.pdf18-04-UA_REPORT_MEDIALITERAСY_INDEX-DM_23-1-final-eng.pdf
18-04-UA_REPORT_MEDIALITERAСY_INDEX-DM_23-1-final-eng.pdf
 
ECONOMIC CONTEXT - LONG FORM TV DRAMA - PPT
ECONOMIC CONTEXT - LONG FORM TV DRAMA - PPTECONOMIC CONTEXT - LONG FORM TV DRAMA - PPT
ECONOMIC CONTEXT - LONG FORM TV DRAMA - PPT
 
Meghan Sutherland In Media Res Media Component
Meghan Sutherland In Media Res Media ComponentMeghan Sutherland In Media Res Media Component
Meghan Sutherland In Media Res Media Component
 
call girls in Kamla Market (DELHI) 🔝 >༒9953330565🔝 genuine Escort Service 🔝✔️✔️
call girls in Kamla Market (DELHI) 🔝 >༒9953330565🔝 genuine Escort Service 🔝✔️✔️call girls in Kamla Market (DELHI) 🔝 >༒9953330565🔝 genuine Escort Service 🔝✔️✔️
call girls in Kamla Market (DELHI) 🔝 >༒9953330565🔝 genuine Escort Service 🔝✔️✔️
 
Final demo Grade 9 for demo Plan dessert.pptx
Final demo Grade 9 for demo Plan dessert.pptxFinal demo Grade 9 for demo Plan dessert.pptx
Final demo Grade 9 for demo Plan dessert.pptx
 
Computed Fields and api Depends in the Odoo 17
Computed Fields and api Depends in the Odoo 17Computed Fields and api Depends in the Odoo 17
Computed Fields and api Depends in the Odoo 17
 
Framing an Appropriate Research Question 6b9b26d93da94caf993c038d9efcdedb.pdf
Framing an Appropriate Research Question 6b9b26d93da94caf993c038d9efcdedb.pdfFraming an Appropriate Research Question 6b9b26d93da94caf993c038d9efcdedb.pdf
Framing an Appropriate Research Question 6b9b26d93da94caf993c038d9efcdedb.pdf
 

pharmacovigilance-111031093044-phpapp01.pdf

  • 2. What is Pharmacovigilance (PV)? The science and activities relating to the detection, assessment, understanding and prevention of adverse effects or any other medicine-related problem – World Health Organization
  • 3. Pharmaco - Vigilance  Pharmaco = medicine  Vigilare = to watch  alert watchfulness  wakefulness  watchfulness in respect of danger; care; caution; circumspection  the process of paying close and continuous attention
  • 4. Definition  Adverse Drug Reaction  "A response to a drug which is noxious and unintended, and which occurs at doses normally used in man for the prophylaxis, diagnosis, or therapy of disease, or for the modification of physiological function."  Adverse Event  Any untoward medical occurrence that may present during treatment with a pharmaceutical product but which does not necessarily have a causal relationship with this treatment  Side Effect  Any unintended effect of a pharmaceutical product occurring at doses normally used in man which is related to the pharmacological properties of the drug
  • 5. The Aims of Pharmacovigilance  To improve patient care and safety  To improve public health and safety  To contribute to the assessment of benefit, harm, effectiveness and risk of medicines  To promote understanding, education and clinical training
  • 6. What to Report? SERIOUS ADRS  A serious adverse event (experience) or reaction is any untoward medical occurrence that at any dose:  results in death,  is life-threatening,  requires inpatient hospitalization of prolongation of existing hospitalization,  is a congenital anomaly/birth defect. NOTE: The term “life-threatening” in the definition of “serious” refers to an event in which the patient was at risk of death at the time of the event; it does not refer to an event which hypothetically might have caused death if it was more severe.
  • 7. Adverse Reactions:Possible Causes  Intrinsic factors of the drug  Pharmacological  Idiosyncratic  Carcinogenicity, Mutagenicity  Teratogenicity  Extrinsic factors  Adulterants  Contamination  Underlying medical conditions  Interactions  Wrong usage
  • 8. What Should be Reported  New drugs  Report all suspected reactions including minor ones  For established or well known drugs  All serious, unexpected, unusual ADRs  Change in frequency of a given reaction  ADRs to generics not seen with innovator products  ADRs to traditional medicines
  • 9. What Should be Reported  All suspected drug-drug, drug-food, drug-food supplement interactions  Statement highlighting marine source of supplements such as glucosamine so that can be avoided by those with allergy to sea food  ADRs associated with drug withdrawals  ADRs due to medication errors  eg vincristine given IT  ADRs due to lack of efficacy or suspected pharmaceutical defects
  • 10. Why ADRs are important ?  5% of hospital admissions  Death of 1 in 1000 medical inpatients  Complicates drug therapy  Decrease compliance
  • 11. Why ADRs are important ? 30 – 50% of all ADRs are preventable
  • 12. Why do we need pharmacovigilance?
  • 13. Why do we need pharmacovigilance? Reason 1:  Humanitarian concern –  Insufficient evidence of safety from clinical trials  Animal experiments  Phase 1 – 3 studies prior to marketing authorization
  • 14. Why do we need pharmacovigilance? Reason 2  Medicines are supposed to save lives  Dying from a disease is sometimes unavoidable; dying from a medicine is unacceptable. WHO. Geneva 2005
  • 15. Why do we need pharmacovigilance? Reason 3: ADRs are expensive !!  6.5% of admissions are due to ADRs  Seven 800-bed hospitals are occupied by ADR patients
  • 16. Cost of ADRs ?  ADR related cost to the country exceeds the cost of the medications themselves
  • 17. Why do we need pharmacovigilance? Reason 4:  Promoting rational use of medicines and adherence
  • 18. Pharmacovigilance system  Records medication related errors  Analyses those errors  Implements interventions  Promotes patient safety  Prevent 'preventable errors' Actionable learning system ARGUS – ARIS Global – Phase Forward (Empirica)
  • 19. Passive - Proactive Future Pro-Active State Risk Management Aggregate Reporting Signal Detection Adverse Case Management
  • 20. Passive - Proactive Current Passive State Risk Management Signal Detection Aggregate Reporting
  • 21. What can we do?
  • 22. What can we do?  Develop procedures for the identification, reporting and follow up of adverse drug events
  • 23. What can we do?  Assess the current technology used in the drug safety process and assist in implementation of new systems
  • 24. What can we do?  Evaluate data quality and data integrity controls in place
  • 25. What can we do?  Prepare risk minimization action plan (RiskMAP)
  • 26. What can we do?  Assess current drug safety and pharmacovigilance training programs
  • 27. What can we do?  Reconcile internal processes for recording safety data received from multiple sources
  • 28. For more information: Monica Dema, Manager New Business Development 973.658.3133 Or Monica.Dema@RCMT.com Or @MonicaDema